About Kedrion biopharma
Kedrion Biopharma: Revolutionizing Plasma-Derived Therapies
Kedrion Biopharma is a leading biopharmaceutical company that specializes in the development, production, and distribution of plasma-derived therapies. The company was founded in 2001 and has since been dedicated to improving the lives of patients suffering from debilitating conditions like Hemophilia and Immune Deficiencies.
The company's mission is to provide innovative solutions for patients with rare diseases by leveraging its expertise in plasma-derived therapies. Kedrion's products are designed to address unmet medical needs and improve patient outcomes.
One of Kedrion's core strengths is its commitment to research and development. The company invests heavily in R&D activities aimed at discovering new treatments for rare diseases. Kedrion has a team of highly skilled scientists who work tirelessly to develop new products that can make a difference in the lives of patients.
Kedrion's product portfolio includes a range of plasma-derived therapies such as immunoglobulins, coagulation factors, albumin, and fibrinogen. These products are used to treat various medical conditions including primary immune deficiencies, bleeding disorders like Hemophilia A/B/Von Willebrand Disease (VWD), Alpha-1 Antitrypsin Deficiency (AATD), Hereditary Angioedema (HAE), Kawasaki Disease (KD), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) among others.
One of Kedrion's flagship products is Gamunex®-C which is an intravenous immunoglobulin therapy used for treating primary immune deficiencies such as X-linked agammaglobulinemia (XLA) or common variable immunodeficiency (CVID). This product has been approved by the US FDA since 2003 and has helped thousands of patients worldwide.
Another notable product from Kedrion is Koāte®-DVI which is a freeze-dried factor VIII concentrate used for treating Hemophilia A. This product contains highly purified clotting factor VIII derived from human plasma which helps restore normal blood clotting function in Hemophilia A patients.
In addition to developing innovative products, Kedrion also places great emphasis on quality control measures throughout its manufacturing process. The company adheres strictly to international standards such as Good Manufacturing Practices (GMP) and ISO 9001:2015 certification ensuring that all its products meet high-quality standards before they are released into the market.
Kedrion also operates several state-of-the-art manufacturing facilities across Europe where it produces its range of plasma-derived therapies using advanced technologies like chromatography purification systems among others. These facilities have been designed with patient safety in mind ensuring that all processes are carried out under strict sterile conditions.
The success story behind Kerdiron Biopharma can be attributed not only due their commitment towards innovation but also their dedication towards social responsibility initiatives around the world through their foundation "KEDRION FOR LIFE". They have supported many projects related to health care services especially those related with blood transfusion services across different countries including Italy, USA etc.,
In conclusion, Kerdiron Biopharma stands out as one of the leading companies when it comes down providing innovative solutions for people suffering from rare diseases through their extensive research & development activities along with maintaining high-quality standards throughout their manufacturing process making them one step ahead than other competitors within this industry sector .